Paediatric research studies
An incident and high risk type 1 diabetes cohort - After Diagnosis Diabetes Research Support System-2 (ADDRESS-2)
The purpose of the study is to identify children and adults newly diagnosed with type 1 diabetes and their brothers and sisters (siblings), who might be interested in taking part in future diabetes research studies. We want to collect information and blood samples from these people to understand more about the development and progression of type 1 diabetes, and to help find suitable trials of new treatments or other studies into diabetes that they might want to take part in. When we find suitable trials or diabetes studies we will write to the eligible people to ask if they would be interested in taking part.
Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome; the PREDNOS 2 study.
Children with nephrotic syndrome suffer from disease relapses, where the protein in the urine returns. When these occur, treatment with high dose prednisolone is commenced and this may be associated with a number of side-effects, such as a puffy face, high blood pressure or changes in mood. For this reason, every effort is made to prevent relapses from happening. This generally involves the use of either low dose every other day prednisolone, or other drugs such as levamisole, ciclosporin or mycophenolate mofetil.
It is well know that relapses may be caused by upper respiratory tract infection (URTI– the common cold). The purpose of this study is to see whether giving a six day course of daily prednisolone when children develop an URTI prevents relapses from developing: we will study this in a large population of UK children with relapsing nephrotic syndrome.
A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide
versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs (SANAD-II).
Epilepsy is a common neurological (brain) disorder. Approximately 2-3% of the population will be given a diagnosis of epilepsy by time they reach 60.
A number of new have been approved to treat epilepsy in the United Kingdom in the past few years. These drugs have been shown in research studies to prevent seizures and to be safe. There is as yet, however, no good evidence as to whether they are better at treating epileptic seizures or safer than the standard drugs that have been used for many years.
In this research study – called SANAD-II – we will compare the standard and new antiepileptic drugs to identify which drugs are the most effective and which ones make the best use of NHS resources.